Embecta Corp (EMBC)vsEli Lilly and Company (LLY)
EMBC
Embecta Corp
$3.90
-57.84%
HEALTHCARE · Cap: $547.78M
LLY
Eli Lilly and Company
$987.05
-0.18%
HEALTHCARE · Cap: $862.01B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 6592% more annual revenue ($72.25B vs $1.08B). LLY leads profitability with a 35.0% profit margin vs 12.9%. EMBC trades at a lower P/E of 3.9x. LLY earns a higher WallStSmart Score of 78/100 (B+).
EMBC
Buy56
out of 100
Grade: C
LLY
Strong Buy78
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+78.6%
Fair Value
$46.96
Current Price
$3.90
$43.06 discount
Intrinsic value data unavailable for LLY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Earnings expanding 82.7% YoY
Conservative balance sheet, low leverage
Strong operational efficiency at 29.2%
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.8% YoY
Areas to Watch
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Revenue declined 0.3%
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 33.3x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : EMBC
The strongest argument for EMBC centers on P/E Ratio, EPS Growth, Debt/Equity.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bear Case : EMBC
The primary concerns for EMBC are Altman Z-Score, Market Cap, Return on Equity.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Key Dynamics to Monitor
EMBC profiles as a declining stock while LLY is a growth play — different risk/reward profiles.
EMBC carries more volatility with a beta of 1.05 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 56/100), backed by strong 35.0% margins and 55.5% revenue growth. EMBC offers better value entry with a 78.6% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Embecta Corp
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Embecta Corp (EMBC) is a premier medical technology company specializing in innovative insulin delivery solutions for diabetes management. As a strategic spin-off from Becton, Dickinson and Company, Embecta utilizes state-of-the-art technologies and a diverse product portfolio, including insulin pens and syringes, to optimize patient care and improve health outcomes. With a strong commitment to operational excellence and a customer-centric approach, Embecta is well-positioned to seize growth opportunities in the rapidly evolving diabetes care market, aiming to enhance patient experiences while solidifying its leadership within the industry.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?